Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES
The clinical trial conducted by Rhode Island Hospital investigates the efficacy of sertraline, a selective serotonin reuptake inhibitor (SSRI), in treating psychogenic nonepileptic seizures (NES) associated with comorbid psychiatric disorders such as depression, anxiety, and PTSD. Given the increasing recognition of the psychological underpinnings of NES, this trial addresses a niche yet significant market. If successful, sertraline could be positioned as a first-line treatment option, potentially leading to a competitive advantage in the psychiatric and neurology markets. The results may also support further funding for larger-scale trials, enhancing the commercial viability of sertraline in this indication.
Indication: Convulsion, Non-Epileptic
Modality: small molecule
Target: Serotonin reuptake inhibition (targeting serotonin transporter)
Sponsor: Rhode Island Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Serotonin reuptake inhibition (targeting serotonin transporter)
View original source fields
Condition raw: Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic
Condition normalized: Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Serotonin reuptake inhibition (targeting serotonin transporter)
Target normalized: Serotonin reuptake inhibition (targeting serotonin transporter)